Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Purpose Although improved long-term prognoses for patients with metastatic breast cancer (MBC) have been demonstrated, few reports address overall survival (OS) with sufficient follow-up. Furthermore, the relevance of immunohistological subtypes to OS in MBC has not been clarified. Methods We evaluated, retrospectively, the OS of patients who had been initiated on systemic therapy for MBC between 2000 and 2008. Results The subjects of this study were 527 patients with MBC treated by systemic therapy. The median survival time (MST) was 55.5 months. The MST for each immunohistological subtype was as follows: luminal, 59.9 months; luminal-HER2, not reached; triple-negative, 18.6 months; and HER2-enriched, 49.9 months. According to multivariate analysis, metastasis-free intervals of ≥2 years and treatment with anthracycline for MBC were predictive of better OS. The predictors of shorter OS included disease progression after first-line treatment for MBC, triple-negative, and all histological factors, except papillotubular carcinoma, with liver metastasis, and having three or more initial metastatic sites. Conclusions The prognosis of the patients with MBC in this series was better than that reported before 2000, which is probably attributable to the use of novel, improved pharmacological agents. For example, luminal-HER2 tumors can be treated using both aromatase inhibitors and trastuzumab. Because of the lower toxicities, it is now possible to administer these agents for longer p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
“Some more recent series seem to indicate an improvement in median overall survival [5, 6].”
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-positive ABC.(5-9) ABC is a treatable disease with several available therapies and many others in development.”
Background4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · The Breast · doi:10.1016/j.breast.2016.10.001 · Cited by 228
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Gampenrieder, S. P., Rinnerthaler, G., Tinchon, C., Petzer, A. L., Balić, M., Heibl, S., Schmitt, C. A., Zabernigg, A. F., Egle, D., Sandholzer, M., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01492-x · Cited by 147
“HER2+ /hormone-receptor(HR)+ breast cancer belongs to the subtypes with the most favorable prognosis both in the early and the advanced stage [1, 2].”
Background
Metadata
- Authors
- Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., & Hatake, K.
- Affiliations
- The Cancer Institute Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Jichi Medical University (JP)
- Corresponding author
- Kobayashi, Kokoro
- ORCID
- Venue
- Surgery Today
- Published
- 2015-10-14
- Volume
- 46
- Issue
- 7
- Pages
- 821-826
- ISSN
- 0047-1909 (ISSN-L)
- 0941-1291
- 1436-2813
- OpenAlex
- W1898450115
- Cited by
- 45
- References
- 33
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 2 · 2016: 5
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Surgery Today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- metastatic breast cancer, overall survival, luminal breast cancer, triple-negative breast cancer, HER2-enriched breast cancer, anthracycline chemotherapy, metastasis-free interval, prognostic factors, papillotubular carcinoma, liver metastasis, trastuzumab, aromatase inhibitors
- MeSH terms
- Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Follow-Up Studies, Humans, Immunohistochemistry, Middle Aged, Prognosis, Retrospective Studies, Time Factors, Survival Rate, Erb-b2 Receptor Tyrosine Kinases, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1007/s00595-015-1252-x
- The paper
- Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., Akiyama, F., Iwase, T., Hozumi, Y., Yasuda, Y., & Hatake, K. (2016). Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surgery Today. https://doi.org/10.1007/s00595-015-1252-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.